Heart failure (HF) is a major health, social and economic problem with about 26 million people worldwide currently suffering from HF. Given an aging population and the rising burden of comorbidities, incidence and prevalence are increasing. The risk of hospitalization is associated strongly with the number of comorbidities. Non-cardiovascular comorbidities are responsible for more than half of the hospitalizations and often lead to worse outcomes in patients with HF, especially in those with preserved ejection fraction (HFpEF). Therefore, screening for comorbidities systematically in patients with HF could influence the outcome and the prognosis in patients with HF regardless of ejection fraction (heart failure with reduced (HFrEF), with mildly reduced (HFmrEF), and with HFpEF). Novel biomarkers could be supportive in detecting non-cardiac comorbidities.
Compared to HFpEF comorbidities in patients with HFmrEF are still under-investigated. HF-Comorbidities can be cardiac such as coronary artery disease, arterial hypertension, atrial fibrillation, valvular heart disease, or non-cardiovascular like diabetes mellitus (DM), chronic obstructive pulmonary disease (COPD), renal insufficiency, anemia, iron deficiency, sleep-disordered breathing, skeletal muscle dysfunction (sarcopenia) or wasting disorders in general (cachexia), or psychosocial disorders (depression, anxiety).
Moreover, the treatment of comorbidities may worsen HF, for example, non-steroidal anti-inflammatory drugs (NSAIDS) as therapy for arthritis or chemotherapy for patients with cancer. Additionally, the therapy of HF and the comorbidities could lead to reduced efficacy and further side effects (e.g., beta-blocker and beta-adrenergic agonists for the management of HF and COPD, respectively). On the other hand, treating comorbidities has been proven to improve symptoms of HF (e.g., iron deficiency).
The aim of this Research Topic is to create a collection of articles from basic to clinical research focusing primarily on establishing the diagnosis and optimizing the therapy of non-cardiac HF-comorbidities, especially in those patients with HFpEF and HFmrEF.
Heart failure (HF) is a major health, social and economic problem with about 26 million people worldwide currently suffering from HF. Given an aging population and the rising burden of comorbidities, incidence and prevalence are increasing. The risk of hospitalization is associated strongly with the number of comorbidities. Non-cardiovascular comorbidities are responsible for more than half of the hospitalizations and often lead to worse outcomes in patients with HF, especially in those with preserved ejection fraction (HFpEF). Therefore, screening for comorbidities systematically in patients with HF could influence the outcome and the prognosis in patients with HF regardless of ejection fraction (heart failure with reduced (HFrEF), with mildly reduced (HFmrEF), and with HFpEF). Novel biomarkers could be supportive in detecting non-cardiac comorbidities.
Compared to HFpEF comorbidities in patients with HFmrEF are still under-investigated. HF-Comorbidities can be cardiac such as coronary artery disease, arterial hypertension, atrial fibrillation, valvular heart disease, or non-cardiovascular like diabetes mellitus (DM), chronic obstructive pulmonary disease (COPD), renal insufficiency, anemia, iron deficiency, sleep-disordered breathing, skeletal muscle dysfunction (sarcopenia) or wasting disorders in general (cachexia), or psychosocial disorders (depression, anxiety).
Moreover, the treatment of comorbidities may worsen HF, for example, non-steroidal anti-inflammatory drugs (NSAIDS) as therapy for arthritis or chemotherapy for patients with cancer. Additionally, the therapy of HF and the comorbidities could lead to reduced efficacy and further side effects (e.g., beta-blocker and beta-adrenergic agonists for the management of HF and COPD, respectively). On the other hand, treating comorbidities has been proven to improve symptoms of HF (e.g., iron deficiency).
The aim of this Research Topic is to create a collection of articles from basic to clinical research focusing primarily on establishing the diagnosis and optimizing the therapy of non-cardiac HF-comorbidities, especially in those patients with HFpEF and HFmrEF.